peptide YY


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.
Related to peptide YY: leptin, amylin

pep·tide YY

(pep'tīd)
A hormone released by the small intestine to signal the brain to stop eating.

peptide YY

An appetite-regulating protein released by L cells of the mucosa of the gastrointestinal tract in response to a meal. It binds to cells in the arcuate nucleus of the brain, decreases the desire to eat, and creates a feeling of fullness.
See also: peptide
References in periodicals archive ?
Shine, "Neuropeptide Y and peptide YY have distinct roles in adult mouse olfactory neurogenesis," Journal of Neuroscience Research, vol.
Ghrelin levels dropped, but peptide YY levels did not change significantly.
Peptide YY is a naturally occurring hormone that is believed to function as a physiologic inhibitor of food intake.
Koopmans, "Comparison of the effects of Roux-en-Y gastric bypass and ileal transposition surgeries on food intake, body weight, and circulating peptide YY concentrations in rats," Obesity Surgery, vol.
Le Roux et al., "Constitutional thinness and lean anorexia nervosa display opposite concentrations of peptide YY, glucagon-like peptide 1, ghrelin, and leptin," American Journal of Clinical Nutrition, vol.
It has been proposed that differences in the secretion of gut hormones (ghrelin, GLP1, peptide YY) occurring after SG or RYGB may play a pivotal role in diabetes regression by acting on appetite [41, 42], improving insulin sensitivity, and restoring the first phase of insulin secretion [23,27,28], all effects which, concomitantly to weight loss, participate to the improvement of diabetes.
The use of a duodenal-jejunal bypass liner (DJBL) not only improves hemoglobin [A.sub.1c] and aids weight loss, but also appears to increase levels of glucagons like peptide--l (GLP-1) and peptide YY while in place, according to the findings of a small study.
And levels of an appetite stopper called peptide YY have been shown to increase five times as much in response to food among gastric bypass patients compared with levels in people who didn't get the surgery.
(Bothell, WA) has patented pharmaceutical compositions and methods comprising at least one peptide YY compound and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.
Formerly obese patients who had undergone Roux-en-Y gastric bypass had increased levels of peptide YY (PYY) and glucagon-like peptide 1 (GLP-1) and exaggerated insulin responses immediately following a meal.
Peptide YY (PYY) and ghrelin are gastrointestinal tract-derived hormones involved in the short- and long-term regulation of food intake and energy balance (1, 2).